You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2025

Investigational Drug Information for Molidustat


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Molidustat?

Molidustat is an investigational drug.

There have been 10 clinical trials for Molidustat. The most recent clinical trial was a Phase 3 trial, which was initiated on December 13th 2017.

The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Renal Insufficiency, and Anemia. The leading clinical trial sponsors are Bayer and [disabled in preview].

There are twenty-one US patents protecting this investigational drug and four hundred and three international patents.

Recent Clinical Trials for Molidustat
TitleSponsorPhase
Maintenance Treatment of Renal Anemia in Dialysis SubjectsBayerPhase 3
A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis SubjectsBayerPhase 3
A Study of Molidustat for Correction of Renal Anemia in Dialysis SubjectsBayerPhase 3

See all Molidustat clinical trials

Clinical Trial Summary for Molidustat

Top disease conditions for Molidustat
Top clinical trial sponsors for Molidustat

See all Molidustat clinical trials

US Patents for Molidustat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Molidustat ⤷  Try for Free Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) ⤷  Try for Free
Molidustat ⤷  Try for Free Method for the preparation of triazole compounds BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) ⤷  Try for Free
Molidustat ⤷  Try for Free Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators Pfizer Inc. (New York, NY) ⤷  Try for Free
Molidustat ⤷  Try for Free Bicyclic-fused heteroaryl or aryl compounds Pfizer Inc. (New York, NY) ⤷  Try for Free
Molidustat ⤷  Try for Free Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN) ⤷  Try for Free
Molidustat ⤷  Try for Free Amide-substituted pyridinyltriazole derivatives and uses thereof BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) ⤷  Try for Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Molidustat

Drugname Country Document Number Estimated Expiration Related US Patent
Molidustat Argentina AR105845 2035-08-27 ⤷  Try for Free
Molidustat Australia AU2016311376 2035-08-27 ⤷  Try for Free
Molidustat Brazil BR112018001650 2035-08-27 ⤷  Try for Free
Molidustat Canada CA2996389 2035-08-27 ⤷  Try for Free
Molidustat China CN107949559 2035-08-27 ⤷  Try for Free
Molidustat Denmark DK3341367 2035-08-27 ⤷  Try for Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Molidustat: A Breakthrough in Treating Anemia Associated with Chronic Kidney Disease

Last updated: January 9, 2025

Introduction to Molidustat

Molidustat is a groundbreaking drug that acts as a hypoxia-inducible factor prolyl-hydroxylase inhibitor, which increases the endogenous production of erythropoietin. This hormone is crucial for stimulating the production of hemoglobin and red blood cells, making molidustat a significant advancement in the treatment of anemia associated with chronic kidney disease (CKD)[1][4][5].

Mechanism of Action

Molidustat works by inhibiting the activity of prolyl-hydroxylase enzymes, which are involved in the degradation of hypoxia-inducible factors (HIFs). By stabilizing HIFs, molidustat increases the production of erythropoietin, primarily in the kidneys. This increase in erythropoietin levels stimulates the bone marrow to produce more red blood cells, thereby addressing anemia[4].

Clinical Trials and Efficacy

Molidustat has undergone extensive clinical trials to evaluate its efficacy and safety. The MIYABI trials, which include several phase III studies, have been pivotal in assessing molidustat's performance in patients with renal anemia, both those undergoing dialysis and those not on dialysis.

  • MIYABI Haemodialysis-Correction (HD-C) and MIYABI Peritoneal Dialysis (PD) trials focused on patients receiving dialysis, with the former being a single-arm trial and the latter involving patients treated or untreated with erythropoiesis-stimulating agents (ESAs)[4].
  • MIYABI Haemodialysis-Maintenance (HD-M) was a randomized, active-controlled, double-blinded trial comparing molidustat with darbepoetin alfa in patients on haemodialysis. This trial demonstrated that molidustat was non-inferior to darbepoetin in maintaining hemoglobin levels within the target range[4].

In non-dialysis patients, molidustat was also shown to be non-inferior to darbepoetin in maintaining hemoglobin levels, as evidenced by a study involving 164 patients randomized to either molidustat or darbepoetin[3].

FDA Approval and Regulatory Status

Human Use

Molidustat is currently in Phase III clinical trials for the treatment of anemia caused by CKD in humans. While it has not yet received full FDA approval for human use, the ongoing trials and positive results suggest a promising future for its application in this area[1][4].

Veterinary Use

In a significant development, the US FDA conditionally approved molidustat oral suspension (Varenzin-CA1) in May 2023 for the management of nonregenerative anemia in cats with chronic kidney disease. This approval marks the first drug specifically approved for this condition in felines, offering a novel treatment option where previous treatments were limited to blood transfusions, supplemental iron therapy, and erythropoietin replacement[5].

Market Projections

The global erythropoietin (EPO) market, which includes drugs like molidustat, is expected to experience rapid growth. Here are some key market projections:

  • Global Market Size: The EPO market is projected to grow to $30.92 billion by 2028, with a compound annual growth rate (CAGR) of 12.6% driven by factors such as market competition, biosimilar impact, disease prevalence, and advancements in clinical trials[2].
  • Regional Segmentation: The market is segmented by region, with detailed forecasts for Western Europe, North America, Eastern Europe, and other regions. Each region's market is further segmented by product, drug class, and application, providing a comprehensive view of the market's potential[2].

Competitive Landscape

The EPO market is highly competitive, with several key players involved in the development and distribution of erythropoietin-stimulating agents. Molidustat, with its unique mechanism of action and potential for treating anemia in both humans and animals, is poised to carve out a significant niche in this market.

Safety and Side Effects

The safety profile of molidustat has been evaluated in various clinical trials. While the drug has shown efficacy, it is also important to monitor for potential side effects. The trials have focused on assessing safety, pharmacokinetics, and pharmacodynamics, ensuring that molidustat is well-tolerated and effective in the long term[4].

Potential for Athletic Doping

Due to its ability to increase erythropoietin levels, molidustat has been incorporated into screens for performance-enhancing drugs. This highlights the need for strict regulatory oversight to prevent its misuse in sports[1].

Veterinary Applications

The conditional FDA approval of molidustat for cats with CKD has opened up new avenues for veterinary care. This drug is administered orally once daily for up to 28 days, with the option for repeated treatment after a minimum 7-day pause. It is available by prescription from licensed veterinarians and represents a significant advancement in treating nonregenerative anemia in felines[5].

Key Takeaways

  • Mechanism of Action: Molidustat increases erythropoietin production by inhibiting prolyl-hydroxylase enzymes.
  • Clinical Trials: Positive results in phase III trials for both dialysis and non-dialysis patients.
  • FDA Approval: Conditionally approved for veterinary use in cats with CKD; ongoing trials for human use.
  • Market Projections: Significant growth expected in the global EPO market.
  • Competitive Landscape: Molidustat has the potential to be a key player in the EPO market.
  • Safety and Side Effects: Ongoing monitoring for safety and side effects.

FAQs

What is molidustat and how does it work?

Molidustat is a drug that acts as a hypoxia-inducible factor prolyl-hydroxylase inhibitor, increasing the production of erythropoietin, which in turn stimulates the production of hemoglobin and red blood cells.

What is the current regulatory status of molidustat for human use?

Molidustat is currently in Phase III clinical trials for the treatment of anemia caused by chronic kidney disease in humans and has not yet received full FDA approval.

What is the significance of molidustat's FDA approval for veterinary use?

Molidustat oral suspension (Varenzin-CA1) was conditionally approved by the FDA in May 2023 for the management of nonregenerative anemia in cats with chronic kidney disease, marking the first approved drug for this condition in felines.

How does molidustat compare to other erythropoietin-stimulating agents?

Molidustat has shown non-inferiority to darbepoetin in maintaining hemoglobin levels in clinical trials, making it a promising alternative in the treatment of anemia associated with CKD.

What are the potential side effects of molidustat?

While molidustat has shown a favorable safety profile, ongoing trials continue to monitor for potential side effects to ensure long-term safety and efficacy.

Why is molidustat included in screens for performance-enhancing drugs?

Molidustat's ability to increase erythropoietin levels makes it a potential candidate for misuse in athletic doping, necessitating its inclusion in anti-doping screens.

Sources

  1. Wikipedia: Molidustat
  2. Research and Markets: Erythropoietin (EPO) Global Market Report 2024
  3. Karger: Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Darbepoetin
  4. PubMed: Molidustat for the treatment of renal anaemia in patients with dialysis
  5. Pharmacy Times: FDA Conditionally Approves First Drug for Nonregenerative Anemia in Cats with Chronic Kidney Disease

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.